SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 56.68-2.4%Dec 12 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: sjemmeri who wrote (14467)12/3/2004 10:24:39 AM
From: rkrw   of 52153
 
I think novn is a pretty safe investment at these prices, albeit unexciting. Got hurt with this PG news as they're working on a next gen intrinsa patch for pg. Also concerns their duragesic generic approval may come a bit after mylan's hits the market. So have taken a couple of hits over the past month. novn patches for hrt have been held up well post whi as patches are perceived as safer, less systemic. hrt biz with novartis provides a nice floor.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News